Catecholamine hormones are powerful regulators of the immune system produced by the sympathetic nervous system (SNS). They regulate the adaptive immune system by altering T-cell differentiation into T helper (Th) 1 and Th2 cell subsets, but the effect on Th17 cells is not known. Th17 cells, defined, in part, by chemokine receptor CCR6 and cytokine interleukin (IL)-17A, are crucial for mediating certain pathogen-specific responses and are linked with several autoimmune diseases. We demonstrated that a proportion of human Th17 cells express beta 2-adrenergic receptor (b2AR), a G protein-coupled receptor that responds to catecholamines. Activation of peripheral blood mononuclear cells, which were obtained from venous blood drawn from healthy volunteers, with anti-cluster of differentiation 3 (CD3) and anti-CD28 and with a b2-agonist drug, terbutaline (TERB), augmented IL-17A levels (P < 0.01) in the majority of samples. TERB reduced interferon gamma (IFNc) indicating that IL-17A and IFNc are reciprocally regulated. Similar reciprocal regulation was observed with dbcAMP. Proliferation of Th cells was monitored by carboxyfluorescein diacetate N-succinimidyl ester labeling and flow cytometry with antibody staining for CD3 and CD4. TERB increased proliferation by a small but significant margin (P < 0.001). Next, Th17 cells (CD4 + CXCR3 À CCR6 + ) were purified using an immunomagnetic positive selection kit, which removes all other mononuclear cells. TERB increased IL-17A from purified Th17 cells, which argues that TERB acts directly on Th17 cells. Thus, hormone signals from the SNS maintain a balance of Th cells subtypes through the b2AR.
Introduction
T cells are an essential part of the adaptive immune system; they are responsible for recognizing foreign antigens depicted by the major histocompatibility complex (MHC) on the antigen presenting cells (APC) such as dendritic cells (DC). T cells also maintain immunological memory of the recognized pathogen. T-cell activation is the result of the T-cell receptor (TCR), with the attached cluster of differentiation 3 (CD3) component [1] , responding to antigen/MHC complex, with co-stimulatory signals received through CD28 [1] . T helper (Th) cells are defined by the presence of CD4 marker on their surface [2] . Upon activation, Th cells differentiate into distinct lineages of effector/memory subsets such as Th1, Th2, and Th17 cells that express defining cytokines IFNc, interleukin (IL)-5, and IL-17A [3] [4] [5] [6] . Th17 cells can be identified by chemokine receptor chemokine receptor 6 (CCR6) and transcription factor RAR-related orphan receptor gamma (RORc) [4, 5, 7, 8] . Th cells diversity provides the immune system with the ability to mount an appropriate response against various classes of pathogens [9] . For example, upon infections with Candida albicans and Staphylococcus aureus, Th17 cells are induced [10] . The cytokine IL-17A, which comes primarily from Th17 cells, mediates the production of inflammatory cytokines, such as IL-6 and IL-1, and chemokines CXCL-1,2,5,8, CCL-2 and CCL-20 that in turn leads to the recruitment of neutrophils and macrophages to sites of inflammation [11] [12] [13] . These cells are contributors for inflammatory autoimmune diseases, such as multiple sclerosis, psoriasis, and rheumatoid arthritis [11] [12] [13] [14] .
The balance of Th subsets is primarily determined by the strength of TCR engagement, co-stimulation, and polarizing cytokines produced by APCs. Catecholamine hormones also influence the balance of Th subsets. Catecholamines consist of two main hormones, norepinephrine (NE) and epinephrine, which mediate metabolic changes throughout the body in a fight or flight response. This response is controlled by the sympathetic nervous system (SNS). The SNS releases NE through adrenergic nerves in areas where T cells reside, such as the parenchyma of the lymph nodes and white pulp of the spleen [15] [16] [17] . T cells express the b2 subtype of the adrenergic receptor (AR) family, which responds to catecholamines [18] [19] [20] [21] [22] [23] . ARs are a family of G protein-coupled receptors present in most tissues. The beta 2 adrenergic receptor (b2AR) transduces signals with stimulatory Ga subunit, adenylyl cyclase (AC), and increases the intracellular second messenger cAMP, which in turn activates protein kinase A (PKA). b2AR is encoded by ADRB2 gene, which has common single-nucleotide polymorphisms (SNPs) that lead to missense changes in amino acid residues and influence the pharmacodynamics of the receptor [24, 25] . The effect of b-agonists on Th cells depends on the species of animal, subtype of T cells and type of agonist used. b-agonists such as isoproterenol and fenoterol inhibited IFNc [26] , while NE raises the level of IFNc in Th1 cells [27] . Murine Th1 cells have variable effects in response to b-agonists [18, [21] [22] [23] 28] . Human Th2 cells do not express b2AR or other AR due to histone modifications that prevent the gene from being expressed [20] . However, Th2 cells expand in response to b agonists, since the competing Th1 cells are suppressed [18, 19, 22, 23, 26, [28] [29] [30] [31] . Catecholamines can indirectly influence Th17 differentiation by acting on APCs. DCs provide co-stimulation and cytokines necessary for CD4 cells to function [32] and produce IL-23 cytokine, which is necessary for Th17 expansion [3, 33, 34] . Murine DC treated with b2AR agonist salbutamol made more IL-23, facilitating the differentiation of effector Th17 cells [35] . b2AR stimulation with NE or salbutamol on mice DC induced IL-17A, and it decreased the production of IFNc by CD4 cells [32, 35] . While it is clear that catecholamines influence APCs, there is comparatively less known about how catecholamines directly influence Th17 cells. We tested the hypothesis that b-agonists modulate Th17 responses using a b2-specific agonist, terbutaline (TERB). In the majority of samples tested, TERB increased IL-17A production in activated peripheral blood mononuclear cells (PBMCs) and concomitantly decreased IFNc production. Purified Th17 cells treated with TERB had elevated IL-17A levels and decreased IFNc.
Results

Expression and function of b2AR on Th17 cells
To determine if Th17 cells express this receptor, PBMCs obtained from healthy human subjects were stained with antibody specific for human b2AR. Th17 cells were gated based on the expression of CD3, CD4 and the chemokine receptor CCR6 (Fig. 1A) . A proportion of Th17 cells expressed b2AR (Fig. 1B) . The CCR6-negative fraction expressed negligible amounts of b2AR (data not shown). Next, PBMCs were activated with a T-cell-specific stimulus in the absence or presence of TERB, which is a b2AR-specific agonist. When PBMCs were exposed to only TERB without the activation stimulus, there were no cytokines detectable in the supernatant (data not shown). Upon activation in the presence of TERB, an increase of IL-17A concentration was observed in the majority of the samples ( Fig. 2A) . A minority of the activated samples showed a trend of decreased IL-17A upon treatment with TERB ( Fig. 2A) . When data were pooled together, the level of IL-17A produced by activated cells was increased by approximately 1.3-fold (P < 0.01) upon treatment with TERB (Fig. 2B) . TERB decreased IFNc concentrations in the subjects' samples to about 0.6-fold of the activated control group (Fig. 2C,D) . The TERB effect on IL-17A and IFNc was attenuated by the b2AR-specific antagonist ICI 118, 551 (Fig. 2B,D) . Together, these data demonstrate that a proportion of Th17 cells express a functional b2AR, and that exposure of PBMC to a b2AR agonist tends to increase IL-17A and decrease IFNc.
It was surprising that TERB did not increase IL-17A levels in all subjects' PBMC samples. IFNc decreased in those samples indicating that they were still responsive to the drug. To evaluate the reproducibility of the results, a series of test/re-test experiments were performed. Representative subjects gave two blood samples drawn at least 1 week apart. For subject 1, where TERB augmented IL-17A in the first sample, TERB still augmented IL-17A in the second sample (Fig. 3A,B) . For subject 2, where TERB reduced IL-17A in the first sample, TERB still reduced IL-17A in the second sample (Fig. 3C,D) . Thus, the pattern of the different responses was reproducible.
Effect of b2-agonist on proliferation
To determine if the effect of b2-agonist on cytokine levels was related to proliferation, PBMCs were stained with the fluorescent dye carboxyfluorescein diacetate succinimidyl ester (CFDASE) prior to incubation with the reagents. As expected, without the activating stimulus, cells retained a high level of fluorescence signifying that they did not proliferate (Fig. 4A ). Upon activation, nearly 50% of Th cells had divided; upon activation with TERB, about 60% of Th cells had divided (Fig. 4B,C ). This effect was abolished by the addition of b2 antagonist (Fig. 4D ). Pooling data together from several samples revealed that TERB increased proliferation by~1.1-fold (Fig. 4E ). All subjects PBMCs had a slightly elevated proliferation response when TERB was added, regardless of whether the IL-17A went up or did not change (data not shown). Cell viability, obtained from trypan blue counting of the samples, was constant through all conditions (Fig. 4F ).
cAMP promotes IL-17A and inhibits IFNc
The results with TERB, which is known to activate a G protein-coupled receptor, suggest that cAMP pathway promotes IL-17A production by Th cells while inhibiting IFNc. To test this using an alternate approach, samples were activated in the presence of dibutyryl cAMP (dbcAMP), which is a nonhydrolysable analog of cAMP. A higher level of IL-17A was detected in the cell culture supernatants of activated samples treated with dbcAMP (P < 0.01), relative to the activation control group (Fig. 5A) . The amount of IL-17A in the presence of dbcAMP had a trend to be higher than the amounts measured in the presence of TERB (Fig. 5A ). IFNc levels were decreased (P < 0.0001) by dbcAMP in activated samples, relative to the activation group, which was similar to the effects of TERB (Fig. 5B) . Thus, cAMP is stimulatory for IL-17A while it has an opposite effect on IFNc.
Effect of b2AR on purified Th17 cells
The previous experiments used PBMC, which contains Th cells, and various other immune cell populations. To determine if the agonist effects were direct and specific for Th17 cells, immunomagnetic positive selection kit was used to prepare a purified fraction of Th17 cells, where live lymphocytes were 85.6% ( + were 93.2% positive for the CCR6 marker of Th17 cells (Fig. 6C) . The purified Th17 samples were then activated with a T-cell-specific stimulus of anti-CD3 and anti-CD28 coated beads. TERB increased the IL-17A levels and decreased IFNc detected in the supernatants of purified Th17 cells (Fig. 6D,E ). This demonstrates that the effect seen by TERB was a likely due to a direct effect on Th17 cells and not due to other cells that could be found in the PBMC mixture. A schematic diagram that represents TERB and possible reciprocal regulation on IL-17A and IFNc cytokine in Th cells is shown in Fig. 7 .
Discussion
Expression and function of b2AR on Th17 cells T-cell differentiation is determined by a number of factors including the strength of TCR-signaling, co-stimulation and polarizing cytokines. Catecholamine hormones also influence this process by acting through ARs. We demonstrated that a proportion of Th17 cells express the b2AR and that a b2-specific agonist augments IL-17A production. The cells that expressed Unpaired t-test *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Error bars show the standard deviation.
b2AR were likely to be previously activated in vivo due to the expression of CCR6, a chemokine receptor present on effector and memory Th17 cells [7] . These results indicate that a proportion of Th17 cells express b2AR and should, therefore, respond to b2AR agonists. We found that TERB increased IL-17A in PBMCs and purified Th17 cells, but inhibited IFNc. The effect on IFNc is consistent with previous reports where Th1 cells responses are inhibited by adrenergic agonists [21, 26, 36] . However, there is a controversy in the literature in results related to adrenergic agonists and Th1 cells. Reports have shown that treatment with adrenergic agonist increases Th1 cytokines [23, 27] or inhibits Th1 cells [32] . The experimental systems can explain the difference in Th1 cytokine levels obtained by our study and other reports. The timing and order of the addition of the adrenergic agonist and activation stimulus might alter the responses [22, 37] . Another example of reciprocal regulation was seen with prostaglandin E2 (PGE 2 ), a proinflammatory chemical that signals through a G-protein-coupled receptor. PBMCs treated with PGE 2 produced more IL-17A and less IFNc [38] . Reciprocal regulation also occurred when Th17 cells were cultured with mesenchymal stem cells that produced and secreted PGE 2 [38, 39] . Thus, agents that cause G protein signaling and elevate cAMP tend to promote IL-17A responses while inhibiting IFNc. The theoretical summary mechanism of action of how the IL-17A and IFNc can be influenced by TERB is shown in Fig. 7 .
Terbutaline augmented IL-17A in the majority of PBMC samples tested; however, there were a minority of subjects' PBMC that showed no change in IL-17A or a downwards trend in IL-17A in response to TERB. All of the samples tested had more IL-17A with dbcAMP exposure which points to differences in the upstream b2AR receptor pathway or the receptor itself. Common polymorphisms exist for the ADRB2 gene [25] . In asthma cohorts, the variability of lung capacity responses to b agonists has been correlated to polymorphisms in the ADRB2 gene, which supports the idea that there is a link between gene and function for adrenergic drugs [40] [41] [42] . A recent study did not find a correlation between the genotype of ADRB2 and IFNc responses to isoproterenol in T cells [24] . To date, there is no adequate explanation as to why ADRB2 genotype is related to pharmacodynamics of the drug-receptor interaction. We are currently investigating the link between ADRB2 polymorphisms and the IL-17A TERB phenotype.
Effect of b2-agonist on proliferation
We observed a small but significant proliferative effect on Th cells activated and treated with TERB. An antiproliferation effect on T cells has been reported with various adrenergic agonists such as isoproterenol, fenoterol, NE, and the inflammatory mediator PGE 2 , which was among the strongest proliferation inhibitors [43] [44] [45] [46] [47] [48] [49] [50] . However, TERB is relatively weak in comparison with these agonists [51] . Co-stimulation also partially reverses the anti-proliferative effect [52] . The activation mix contained anti-CD28 co-stimulatory antibodies, which may account for why we did not see an anti-proliferative effect.
cAMP pathway promotes IL-17A
We demonstrated that dbcAMP augments IL-17A levels in activated PBMCs. Generally, cAMP is thought to inhibit T-cell activation and proliferation [53] . For Th1 cells, the cAMP pathway has been shown to be inhibitory [18] . The fact that dbcAMP augmented IL-17A suggests that the signaling pathways in Th17 cells are different than other T cells. It has been shown that upstream signaling compartments are notably different in Th17 cells than other subsets [54] . Moreover, knockouts of the stimulatory Ga subunit decreased cAMP accumulation in Th cells, which in turn reduced the differentiation of Th17 cells [55] . Thus, Th17 cells appear to require the cAMP-PKA pathway for their development.
Effect of b2AR on purified Th17 cells
Performing the experiment on highly purified Th17 cells revealed that TERB augmented IL-17A levels to a similar extent as seen in the PBMC mix. b2AR agonist augmented the levels of IL-17A on highly purified Th17 cells. There was detectable IFNc in these cells, and treatment with b2AR agonist decreased the level of IFNc. The source of the IFNc in the purified Th17 cells could be from Th17 cells that can produce IFNc as well or residual Th1 cells [10, 56, 57] . The fact that TERB modulated purified Th17 responses rules out the involvement of APCs in the observed effects, since the magnetic columns remove myeloid cells.
Potential physiological relevance
Sustained activity of the SNS could result in NE secretion into the T-cell areas of the secondary lymphoid tissues which primes DCs to favor Th17 differentiation after the naive cells turn to effectors [32, 35] . In addition, lymphocytes are also capable of synthesizing catecholamines through the action of tyrosine hydroxylase, which may play a part in auto-regulating the balance of Th cell subsets [58] [59] [60] [61] [62] [63] [64] . There is a balance of subtypes of Th cells that is maintained within the body to effectively eliminate pathogens and keep a healthy immune system. The differential production of cytokines showed that stimulation of the b2AR with TERB augments the Th17 cell population. The parasympathetic nervous system, which generally opposes the function of the SNS, will inhibit Th17 cells via the neurotransmitter acetylcholine acting through the a7nAChR, a nicotinic receptor that responds to acetylcholine from cholinergic nerves [65] . Thus, sympathetic signals boost Th17 responses in most people, while parasympathetic signals inhibit Th17 responses.
Materials and methods
Activation and treatment of cells
Venous blood was drawn from healthy volunteers after obtaining informed consent. The project was approved by the Concordia University Human Research Ethics Committee. Our board of ethics is independent and conforms to the Helsinki guidelines. A venipuncture needle was used to draw up to six heparinized vacutainer tubes (BD, Franklin Lakes, NJ, USA). Whole blood was processed through a ficoll-hypaque (GE healthcare, Mississauga, ON, Canada) density gradient centrifugation technique as previously described [66] . 
Measuring proliferation and differentiated cells
Prior to plating, PBMCs were labeled with (6)-CFDASE (Sigma Aldrich, ON, Canada) as previously described [67] .
In brief, cells were suspended in prewarmed R10 media and mixed with CFDASE diluted in phosphate-buffered saline (PBS), at a final concentration of 5 lM. This remained at room temperature for 5 min and was then washed three times with PBS containing 10% FBS [67] . Cells were then used for the experiments. On day 4, cell staining was done according to the published protocol [39] . The conjugated antibodies were CD3-PercP and CD4-APC (eBioscience) at 1 : 10 dilution. Samples were transferred to micro-centrifuge tubes and analyzed by flow cytometry (FACS verse BD Bioscience, Mississauga, ON, Canada). In order to observe differentiation, different cytokines were measured by enzyme-linked immunosorbent assay (ELISA), according to the manufacturer's instructions (eBioscience).
Detection of b2AR by flow cytometry
Peripheral blood mononuclear cells were stained with either the primary antibody b2AR rabbit polyclonal (1 mgÁmL À1 ) at a 1 : 50 dilution or a rabbit Ig antibody, used as a negative control (5 mgÁmL À1 ), at a 1 : 250 dilution. The secondary goat anti-rabbit-FITC molecular was added at a 1 : 500 dilution. Primary antibodies for CD3-PercP, CD4-APC, and CCR6-PE were added (eBioscience, Mississauga, ON, Canada) to facilitate identification of Th cells in the PBMC mixture. Cells were washed twice with PBS and resuspended in 1% formaldehyde. Samples were transferred to micro-centrifuge tubes and analyzed by the Acuri flow cytometer (BD Bioscience). 
